Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pitavastatin: A Review in Hypercholesterolemia
Sheridan M. Hoy
American Journal of Cardiovascular Drugs (2017) Vol. 17, Iss. 2, pp. 157-168
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Association Between Uric Acid to HDL Cholesterol Ratio and Diabetic Complications in Men and Postmenopausal Women
Yan Xuan, Wen Zhang, Yuying Wang, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 167-177
Open Access | Times Cited: 20
Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux
Angie M. Torres-Adorno, Heidi Vitrac, Yuan Qi, et al.
Oncogene (2018) Vol. 38, Iss. 12, pp. 2135-2150
Open Access | Times Cited: 37
Personalized Statin Therapy: Targeting Metabolic Processes to Modulate the Therapeutic and Adverse Effects of Statins
Zhuangqi Shi, Shuxin Han
Heliyon (2025) Vol. 11, Iss. 1, pp. e41629-e41629
Closed Access
Elucidating the binding specificity of interactive compounds targeting ATP-binding cassette subfamily G member 2 (ABCG2)
Pawan Kumar, Indu Kumari, Rajendra Prasad, et al.
Molecular Diversity (2025)
Open Access
Progress of potential drugs targeted in lipid metabolism research
Kai Liang, Jianye Dai
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 16
Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study
Bahar Arıcan Tarım, Francesco Fıcı, İstemihan Tengiz, et al.
Yonsei Medical Journal (2023) Vol. 64, Iss. 3, pp. 175-175
Open Access | Times Cited: 9
Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022
Pengfei Xu, Lijun Zhu, Desheng Zhang, et al.
Results in Chemistry (2024) Vol. 7, pp. 101446-101446
Open Access | Times Cited: 3
COSMIC project: consensus on the objectives of the metabolic syndrome in clinic
Juan Pedro‐Botet, Juan F. Ascaso, Vivencio Barrios, et al.
Diabetes Metabolic Syndrome and Obesity (2018) Vol. Volume 11, pp. 683-697
Open Access | Times Cited: 25
Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis
Mingjie Yuan, Shuyi Han, Yanfei Jia, et al.
International Journal of Clinical Practice (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 12
Lipid metabolism, amino acid metabolism, and prostate cancer: a crucial metabolic journey
Lin Chen, Yuxin Xu, Yuanshuo Wang, et al.
Asian Journal of Andrology (2023) Vol. 26, Iss. 2, pp. 123-134
Open Access | Times Cited: 6
An efficient biocatalytic oxidative dehydroaromatization approach for the construction of quinolines enabled by monoamine oxidase with molecular oxygen
Huanhuan Jin, Shuyun Ju, Haoran Yu, et al.
Green Chemistry (2023) Vol. 25, Iss. 13, pp. 5296-5303
Closed Access | Times Cited: 5
Pitavastatin protects against neomycin-induced ototoxicity through inhibition of endoplasmic reticulum stress
Yunhao Wu, Wei Meng, Ming Guan, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 8
Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation
Sophia F. Oliai, Daniel C. Shippy, Tyler K. Ulland
Journal of Neuroimmunology (2024) Vol. 391, pp. 578364-578364
Closed Access | Times Cited: 1
Pitavastatin ameliorates myocardial damage by preventing inflammation and collagen deposition via reduced free radical generation in isoproterenol-induced cardiomyopathy
Ramsha Iqbal, Md Sayeed Akhtar, Md Quamrul Hassan, et al.
Clinical and Experimental Hypertension (2018) Vol. 41, Iss. 5, pp. 434-443
Closed Access | Times Cited: 11
Statin treatment and increased diabetes risk. Possible mechanisms
Elisenda Climent, David Benaiges, Juan Pedro‐Botet
Clínica e Investigación en Arteriosclerosis (2019) Vol. 31, Iss. 5, pp. 228-232
Closed Access | Times Cited: 9
Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention
Francesco Fıcı, Gökhan Faikoğlu, Bahar Arıcan Tarım, et al.
High Blood Pressure & Cardiovascular Prevention (2022) Vol. 29, Iss. 2, pp. 137-144
Closed Access | Times Cited: 6
Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis
Ruping Cai, Chen Chang, Xingjie Zhong, et al.
Cardiovascular Innovations and Applications (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 3
Evaluation of the Pharmacokinetic Drug–Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers
Hae Won Lee, Woo Youl Kang, W. Jung, et al.
Pharmaceutics (2020) Vol. 12, Iss. 9, pp. 869-869
Open Access | Times Cited: 8
Statin treatment and increased diabetes risk. Possible mechanisms
Elisenda Climent, David Benaiges, Juan Pedro‐Botet
Clínica e Investigación en Arteriosclerosis (English Edition) (2019) Vol. 31, Iss. 5, pp. 228-232
Closed Access | Times Cited: 8
Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin
Lâle Tokgözoğlu, José Luis Zamorano
Drugs in Context (2020) Vol. 9, pp. 1-11
Open Access | Times Cited: 7
RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
Banshi Saboo, Sanjay Agarwal, Brij Makkar, et al.
International Journal of Diabetes in Developing Countries (2022) Vol. 42, Iss. 1, pp. 3-28
Closed Access | Times Cited: 5
A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS)
Jianning Zhang, Yijia Shao, Yin Liu, et al.
Cardiovascular Drugs and Therapy (2018) Vol. 32, Iss. 6, pp. 581-589
Closed Access | Times Cited: 6
Forty‐eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas
Xieda Zhou, Li Wu, Yan Chen, et al.
Journal of Diabetes Investigation (2020) Vol. 12, Iss. 7, pp. 1278-1286
Open Access | Times Cited: 6
Pitavastatin Induces Apoptosis of Cutaneous Squamous Cell Carcinoma Cells through Geranylgeranyl Pyrophosphate-Dependent c-Jun N-Terminal Kinase Activation
Kyung-Il Kim, Seung-Mee Kim, Young‐Yoon Lee, et al.
Annals of Dermatology (2023) Vol. 35, Iss. 2, pp. 116-116
Open Access | Times Cited: 2
Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence
Yolanda Prado, Diego Aravena, Felipe M. Llancalahuén, et al.
Advances in experimental medicine and biology (2023), pp. 25-47
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top